{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:47:18Z","timestamp":1781840838278,"version":"3.54.5"},"reference-count":36,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>In August 2016, the Food and Drug Administration advised US blood centers to screen all whole blood and apheresis donations for Zika virus (ZIKV) with an individual\u2010donor nucleic acid test (ID\u2010NAT) or to use approved pathogen reduction technology (PRT). The cost of implementing this guidance nationally has not been assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>Scenarios were constructed to characterize approaches to ZIKV screening, including universal ID\u2010NAT, risk\u2010based seasonal allowance of minipool (MP) NAT by state, and universal MP\u2010NAT. Data from the 2015 National Blood Collection and Utilization Survey (NBCUS) were used to characterize the number of donations nationally and by state. For each scenario, the estimated cost per donor ($3\u2010$9 for MP\u2010NAT, $7\u2010$13 for ID\u2010NAT) was multiplied by the estimated number of relevant donations from the NBCUS. Cost of PRT was calculated by multiplying the cost per unit ($50\u2010$125) by the number of units approved for PRT. Prediction intervals for costs were generated using Monte Carlo simulation methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Screening all donations in the 50 states and DC for ZIKV by ID\u2010NAT would cost $137 million (95% confidence interval [CI], $109\u2010$167) annually. Allowing seasonal MP\u2010NAT in states with lower ZIKV risk could reduce NAT screening costs by 18% to 25%. Application of PRT to all platelet (PLT) and plasma units would cost $213 million (95% CI, $156\u2010$304).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Universal ID\u2010NAT screening for ZIKV will cost US blood centers more than $100 million annually. The high cost of PRT for apheresis PLTs and plasma could be mitigated if, once validated, testing for transfusion transmissible pathogens could be eliminated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.14164","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T20:35:50Z","timestamp":1496867750000},"page":"1625-1633","source":"Crossref","is-referenced-by-count":27,"title":["Cost projections for implementation of safety interventions to prevent transfusion\u2010transmitted Zika virus infection in the United States"],"prefix":"10.1111","volume":"57","author":[{"given":"Katherine D.","family":"Ellingson","sequence":"first","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"},{"name":"Department of Epidemiology and Biostatistics The University of Arizona College of Public Health Tucson Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew R.P.","family":"Sapiano","sequence":"additional","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"},{"name":"Surveillance Branch, Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Haass","sequence":"additional","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra A.","family":"Savinkina","sequence":"additional","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"},{"name":"Oak Ridge Institute for Science and Education Oak Ridge Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha L.","family":"Baker","sequence":"additional","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"},{"name":"Northrop Grumman Corporation Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Henry","sequence":"additional","affiliation":[{"name":"Office of HIV\/AIDS &amp; Infectious Disease Policy, Office of the Assistant Secretary for Health, US Department of Health &amp; Human Services Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Berger","sequence":"additional","affiliation":[{"name":"Office of HIV\/AIDS &amp; Infectious Disease Policy, Office of the Assistant Secretary for Health, US Department of Health &amp; Human Services Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Kuehnert","sequence":"additional","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar V.","family":"Basavaraju","sequence":"additional","affiliation":[{"name":"Office of Blood, Organ, and Other Tissue Safety, Division of Healthcare Quality Promotion"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13673"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1600297"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1604338"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30776-0"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00562-6"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6534e1"},{"key":"e_1_2_7_8_1","unstructured":"Case counts in the US [Internet]. Atlanta: Centers for Disease Control and Prevention;2017[cited 2017 Feb 6]. Available from:https:\/\/www.cdc.gov\/zika\/geo\/united-states.html."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1509.090442"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.23.30254"},{"key":"e_1_2_7_11_1","unstructured":"Donor screening recommendations to reduce the risk of transmission of Zika virus by human cells tissues and cellular and tissue\u2010based products: guidance for industry. Silver Spring (MD): U.S. Food and Drug Administration;2016."},{"key":"e_1_2_7_12_1","unstructured":"Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components: guidance for industry. Silver Spring (MD): U.S. Food and Drug Administration;2016."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13681"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1607262"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12707"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-737981"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6524e2"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6503e1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6538e1"},{"key":"e_1_2_7_20_1","unstructured":"Guidance for industry: use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion. Silver Spring (MD): U.S. Food and Drug Administration;2009."},{"key":"e_1_2_7_21_1","unstructured":"Guidance for industry: nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV\u20101) and hepatitis C virus (HCV): testing product disposition and donor deferral and reentry. Silver Spring (MD): U.S. Food and Drug Administration;2010."},{"key":"e_1_2_7_22_1","first-page":"8","article-title":"On the seasonal occurrence and abundance of the Zika virus vector mosquito Aedes aegypti in the contiguous United States","author":"Monaghan AJ","year":"2016","journal-title":"PLoS Curr"},{"key":"e_1_2_7_23_1","unstructured":"USGS and CDC disease maps [Internet]. Reston (VA): U.S. Department of the Interior U.S. Geological Survey; 2016 [cited yyyy mmm dd]. Available from:https:\/\/diseasemaps.usgs.gov\/index.html."},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","DOI":"10.1111\/trf.14165","article-title":"Continued Decline in Blood Collection and Transfusion in the United States \u2013 2015","author":"Ellingson K","year":"2017","journal-title":"Transfusion"},{"key":"e_1_2_7_25_1","unstructured":"Code of Federal Regulations Charging for investigational new drugs under an IND title 21 sec. 312.8."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00392.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00379.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.00644.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-7-200510040-00007"},{"key":"e_1_2_7_30_1","unstructured":"Population estimates by state and age. Washington (DC): U.S. Census Bureau;2015."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80288-6"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02704.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12232"},{"key":"e_1_2_7_34_1","unstructured":"114th meeting of the Blood Products Advisory Committee. Silver Spring (MD): Food and Drug Administration Center for Biologics Evaluation and Research;2016."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6506e2"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1507761"},{"key":"e_1_2_7_37_1","unstructured":"Cerus announces agreement with BARDA for potential funding of up to approximately $180 million to advance its INTERCEPT red blood cell program [press release]. Concord (CA): Cerus Corp.;2016."}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.14164","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.14164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T16:45:51Z","timestamp":1719247551000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.14164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":36,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/trf.14164"],"URL":"https:\/\/doi.org\/10.1111\/trf.14164","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}